Safety of COVID-19 mRNA vaccination in children with chronic urticaria
J Allergy Clin Immunol Pract
.
2023 Apr;11(4):1310-1313.e2.
doi: 10.1016/j.jaip.2022.12.029.
Epub 2023 Jan 5.
Authors
Catherine K Zhu
1
,
Alex Nguyen
2
,
Connor Prosty
2
,
Sofianne Gabrielli
2
,
Vera Laboccetta
3
,
Greg Shand
3
,
Pasquale Mulé
4
,
Elena Netchiporouk
5
,
Michelle Le
5
,
Xun Zhang
3
,
Danbing Ke
3
,
Sharon Baum
6
,
Reman Hakroush
7
,
Shoshana Greenberger
7
,
Moshe Ben-Shoshan
4
Affiliations
1
Faculty of Medicine, McGill University, Montreal, QC, Canada. Electronic address:
[email protected]
.
2
Faculty of Medicine, McGill University, Montreal, QC, Canada.
3
Centre for Outcome Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, QC, Canada.
4
Division of Pediatric Allergy and Clinical Immunology, Department of Pediatrics, McGill University Health Centre, Montreal, QC, Canada.
5
Division of Dermatology, McGill University Health Centre, Montreal, QC, Canada.
6
Department of Dermatology, Chaim Sheba Medical Center, Tel-Aviv University, Sackler School of Medicine, Tel HaShomer, Israel.
7
Pediatric Dermatology Service, Department of Dermatology, Sheba Medical Center, Sackler School of Medicine, Ramat Gan, Israel.
PMID:
36621604
PMCID:
PMC9812818
DOI:
10.1016/j.jaip.2022.12.029
No abstract available
MeSH terms
COVID-19* / prevention & control
Child
Chronic Urticaria*
Humans
RNA, Messenger
Urticaria*
Vaccination
Substances
RNA, Messenger